These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9408692)

  • 21. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection.
    Dominguez J; Kompatzki A; Foradori A; Norambuena R
    Transplant Proc; 2003 Nov; 35(7):2522-3. PubMed ID: 14612002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects.
    Bergman AJ; Burke J; Larson P; Johnson-Levonas AO; Reyderman L; Statkevich P; Kosoglou T; Greenberg HE; Kraft WK; Frick G; Murphy G; Gottesdiener K; Paolini JF
    J Clin Pharmacol; 2006 Mar; 46(3):321-7. PubMed ID: 16490808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of cyclosporine A to tacrolimus following heart transplantation.
    Mathieu P; Carrier M; White M; Pellerin M; Perrault LP; Pelletier G; Pelletier LC
    Can J Cardiol; 1999 Nov; 15(11):1229-32. PubMed ID: 10579737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice.
    Vessie EL; Hirsch GM; Lee TD
    Transpl Immunol; 2005 Oct; 15(1):35-44. PubMed ID: 16223671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of renal transplants from pediatric donors <5 yr of age.
    El-Sabrout R; Buch K
    Clin Transplant; 2005 Jun; 19(3):316-20. PubMed ID: 15877791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
    Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
    Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased effect of immunosuppression on immunocompetence in African--Americans after kidney and liver transplantation.
    Nagashima N; Watanabe T; Nakamura M; Shalabi A; Burdick JF
    Clin Transplant; 2001 Apr; 15(2):111-5. PubMed ID: 11264637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporin twice or three times daily dosing in pediatric transplant patients - it is not the same!
    Filler G; de Barros VR; Jagger JE; Christians U
    Pediatr Transplant; 2006 Dec; 10(8):953-6. PubMed ID: 17096765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE; Keogh AM; McLachlan AJ
    J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
    Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
    Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
    Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic monitoring of cyclosporine A].
    Komzáková I; Safarcík K; Brozmanová H; Grundmann M
    Ceska Slov Farm; 2002 Jul; 51(4):159-67. PubMed ID: 12183901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients.
    Paydaş S; Balal M; Sertdemir Y; Seyrek N; Karayaylali I
    Ren Fail; 2005; 27(4):409-13. PubMed ID: 16060128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Host thymectomy and cyclosporine lead to unstable skin graft tolerance after class I mismatched allogeneic neonatal thymic transplantation in mice.
    Rodríguez-Barbosa JI; Haller GW; Zhao G; Sachs DH; Sykes M
    Transpl Immunol; 2005 Oct; 15(1):25-33. PubMed ID: 16223670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketoconazole inhibits cyclosporine metabolism in vivo in mice.
    Anderson JE; Blaschke TF
    J Pharmacol Exp Ther; 1986 Mar; 236(3):671-4. PubMed ID: 3950868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries.
    Gerntholtz T; Pascoe MD; Botha JF; Halkett J; Kahn D
    Eur J Clin Pharmacol; 2004 May; 60(3):143-8. PubMed ID: 15083250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats.
    Varela MC; Guzmán M; Molpeceres J; del Rosario Aberturas M; Rodríguez-Puyol D; Rodríguez-Puyol M
    Eur J Pharm Sci; 2001 Feb; 12(4):471-8. PubMed ID: 11231114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.